DK493584A - Fremgangsmaade til inhibering af vaeskt af virus og anti-viralt middel - Google Patents

Fremgangsmaade til inhibering af vaeskt af virus og anti-viralt middel Download PDF

Info

Publication number
DK493584A
DK493584A DK493584A DK493584A DK493584A DK 493584 A DK493584 A DK 493584A DK 493584 A DK493584 A DK 493584A DK 493584 A DK493584 A DK 493584A DK 493584 A DK493584 A DK 493584A
Authority
DK
Denmark
Prior art keywords
virus
procedure
viral agent
inhibiting current
inhibiting
Prior art date
Application number
DK493584A
Other languages
English (en)
Other versions
DK493584D0 (da
DK168061B1 (da
Inventor
Akira Kaji
Original Assignee
Akira Kaji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP58192350A external-priority patent/JPH0740934B2/ja
Priority claimed from JP59049321A external-priority patent/JPS60193922A/ja
Application filed by Akira Kaji filed Critical Akira Kaji
Publication of DK493584D0 publication Critical patent/DK493584D0/da
Publication of DK493584A publication Critical patent/DK493584A/da
Application granted granted Critical
Publication of DK168061B1 publication Critical patent/DK168061B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK493584A 1983-10-17 1984-10-16 Med mrna hybridiserbart anti-viralt middel DK168061B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP58192350A JPH0740934B2 (ja) 1983-10-17 1983-10-17 ウイルス増殖阻害方法
JP19235083 1983-10-17
JP4932184 1984-03-16
JP59049321A JPS60193922A (ja) 1984-03-16 1984-03-16 抗ウイルス剤
MTP957 1984-12-12
MT957A MTP957B (en) 1983-10-17 1984-12-12 Method for inhibiting viral propagation and anti-viral agent

Publications (3)

Publication Number Publication Date
DK493584D0 DK493584D0 (da) 1984-10-16
DK493584A true DK493584A (da) 1985-04-18
DK168061B1 DK168061B1 (da) 1994-01-31

Family

ID=39877713

Family Applications (1)

Application Number Title Priority Date Filing Date
DK493584A DK168061B1 (da) 1983-10-17 1984-10-16 Med mrna hybridiserbart anti-viralt middel

Country Status (18)

Country Link
US (1) US4689320A (da)
AT (1) AT392081B (da)
AU (1) AU578625B2 (da)
BE (1) BE900827A (da)
CH (1) CH667593A5 (da)
DE (1) DE3437852A1 (da)
DK (1) DK168061B1 (da)
FR (1) FR2553420B1 (da)
GB (1) GB2148302B (da)
IE (1) IE57987B1 (da)
IT (1) IT1179144B (da)
LU (1) LU85594A1 (da)
MT (1) MTP957B (da)
NL (1) NL8403163A (da)
NZ (1) NZ209840A (da)
PH (1) PH21629A (da)
SE (1) SE466482B (da)
SG (1) SG31088G (da)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580716A (en) * 1985-03-21 1996-12-03 Stephen A. Johnston Parasite-derived resistance
ATE201444T1 (de) * 1985-03-21 2001-06-15 Johnston Stephen Ph D Vom parasit abgeleiteter widerstand
AU612972B2 (en) * 1986-04-02 1991-07-25 Pioneer Hi-Bred International, Inc. Virus resistant plants having antisense rna
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5637573A (en) * 1986-05-23 1997-06-10 Agrawal; Sudhir Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5834185A (en) * 1986-10-28 1998-11-10 Johns Hopkins University Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs, triple helix complexes formed thereby and oligomers used in their formation
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
EP0331939B1 (en) * 1988-02-16 2001-11-14 Greatbatch Gen-Aid, Ltd Modified cells having resistance to retroviral infection
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
CA2489769A1 (en) * 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
WO1990015814A1 (en) * 1989-06-20 1990-12-27 Meiogenics, Inc. Nuclease resistant, single-stranded, non-naturally occurring nucleic acid molecules
CA2065294A1 (en) * 1989-09-01 1991-03-02 Bruno Calabretta Antisense oligonucleotides to c-abl proto-oncogene
ES2113371T3 (es) * 1989-11-16 1998-05-01 Univ Duke Transformacion de celulas epidermicas de tejidos animales con la ayuda de particulas.
US5177198A (en) * 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US6005087A (en) * 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5872232A (en) * 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US5852182A (en) * 1990-01-11 1998-12-22 Isis Pharmaceuticals Inc. Thiol-derivatized oligonucleosides
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
WO1992003568A1 (en) * 1990-08-13 1992-03-05 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5859221A (en) * 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6399754B1 (en) * 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
KR927003044A (ko) * 1990-01-11 1992-12-17 크리스토퍼 케이. 미라벨리 Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6114513A (en) * 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US20030186913A1 (en) * 1990-03-21 2003-10-02 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US6262241B1 (en) * 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
HUT69956A (en) * 1990-08-14 1995-09-28 Isis Pharmaceuticals Inc Methode for inhibition of influenza virus by antiseuse oligonucleotides
NZ239372A (en) * 1990-08-15 1997-06-24 Genta Inc Inhibition of herpes virus infection by antisense oligomers
US5595978A (en) * 1990-08-16 1997-01-21 Isis Pharmaceuticals, Inc. Composition and method for treatment of CMV retinites
WO1992004903A1 (en) * 1990-09-21 1992-04-02 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Method of inhibiting viral production
JPH06501162A (ja) * 1990-09-21 1994-02-10 ユニバーシティ オブ メリーランド ウイルス類の成長または複製を抑制するための組成物および方法
US5942389A (en) * 1990-10-19 1999-08-24 Board Of Trustees Of The University Of Illinois Genes and genetic elements associated with sensitivity to cisplatin
WO1992013972A1 (en) * 1991-02-11 1992-08-20 Thomas Jefferson University Genetically engineered bacteria to identify and produce medically important agents
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
JPH06507911A (ja) * 1991-05-31 1994-09-08 ジンタ・インコーポレイテッド 中性オリゴマーを経皮投与するための組成物及び供給系
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en) * 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
WO1993013114A1 (en) * 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING β-AMYLOID
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
US6521601B1 (en) * 1992-04-14 2003-02-18 Signal Pharmaceuticals, Inc. Method and composition for inhibition of viral replication
US6806084B1 (en) * 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
TW244371B (da) * 1992-07-23 1995-04-01 Tri Clover Inc
US6346614B1 (en) * 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
ATE162198T1 (de) * 1992-07-27 1998-01-15 Hybridon Inc Oligonukleotid alkylphosphonothiate
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US5840708A (en) * 1992-12-14 1998-11-24 Allegheny University Of The Health Sciences Administration of oligonucleotides antisense to dopamine receptor MRNA for diagnosis and treatment of Neurological pathologies
AU684748B2 (en) * 1993-01-21 1998-01-08 Hybridon, Inc. Foldback triplex-forming oligonucleotides
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
AU688364B2 (en) * 1993-07-19 1998-03-12 Gen-Probe Incorporated Oligonucleotides with activity against human immunodeficiency virus
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
ATE247128T1 (de) 1993-09-03 2003-08-15 Isis Pharmaceuticals Inc Aminoderivatisierte nukleoside und oligonukleoside
US6653458B1 (en) 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
US5837852A (en) * 1993-10-14 1998-11-17 Bristol-Myers Squibb Company Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
WO1995030746A1 (en) * 1994-05-10 1995-11-16 The General Hospital Corporation Antisense inhibition of hepatitis c virus
US5733781A (en) * 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
AU3689695A (en) * 1994-09-29 1996-04-19 Nauchno-Proizvodstvennoe Predpriyatie "Farmek" Dna-rna hydrid and a dna preparation, methods of obtaining said hybrid and preparation from sturgeon milt, and a pharmaceutical compound based on said dna-rna hybrid
US6117993A (en) * 1995-05-23 2000-09-12 Hybridon, Inc. Synthons for oligonucleotide synthesis
US5750674A (en) * 1995-05-23 1998-05-12 Hybridon, Inc. Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
US5693773A (en) * 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20080119427A1 (en) * 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US20040023917A1 (en) * 1996-12-31 2004-02-05 Bennett C. Frank Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) * 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6306831B1 (en) 1997-09-12 2001-10-23 Qik Technologies, Inc. Transplacental delivery of oligonucleotides
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN101818145A (zh) * 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
WO1999060167A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
WO1999060012A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6015676A (en) * 1998-07-31 2000-01-18 Epiclone Inc. Method for knocking out gene transcripts by covalently binding of an anti-sense probe
ES2234563T5 (es) * 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP4151751B2 (ja) * 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US20010011126A1 (en) * 1999-09-10 2001-08-02 Bock Elisabeth Marianne Neurogenic compositions and methods
AU2001276691A1 (en) * 2000-08-03 2002-02-18 Matsushita Electric Industrial Co., Ltd. Brushless motor and method of manufacturing the brushless motor
RU2172632C1 (ru) * 2000-12-01 2001-08-27 Каплина Элли Николаевна Способ получения иммунотропного противовирусного препарата
RU2188659C1 (ru) * 2001-04-20 2002-09-10 ООО Научно-производственное фармацевтическое предприятие "Полидан" Фармацевтическая композиция для терапии человека, обладающая иммунотропным действием
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
AU2003256325A1 (en) * 2002-06-26 2004-01-19 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
US20040009483A1 (en) * 2002-07-12 2004-01-15 Ilsley Diane D. Method of linear mRNA amplification using total RNA
EP1546344A4 (en) * 2002-09-18 2007-10-03 Isis Pharmaceuticals Inc EFFICIENT PRODUCTION OF TARGET RNAS USING SINGLE AND DOUBLE-STRONG OLIGOMER COMPOUNDS
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
WO2004071430A2 (en) * 2003-02-05 2004-08-26 University Of Massachusetts RNAi TARGETING OF VIRUSES
US8084432B2 (en) * 2003-02-13 2011-12-27 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US8101585B2 (en) * 2006-08-04 2012-01-24 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
US9708360B2 (en) 2013-09-30 2017-07-18 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1107929A (en) * 1965-11-14 1968-03-27 Yissum Res Dev Co Organotin derivatives of natural and synthetic polymers
JPS5735516A (en) * 1980-08-11 1982-02-26 Yamasa Shoyu Co Ltd Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
JPS5767518A (en) * 1980-09-17 1982-04-24 Yamasa Shoyu Co Ltd Radiosensitizing agent or agent for increasing effect of radiomimetic substance
US4511713A (en) * 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4358586A (en) * 1980-12-23 1982-11-09 Harvey Rubin Detection and isolation of endorphin mRNA using a synthetic oligodeoxynucleotide
DE3106982A1 (de) * 1981-02-25 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach "neues tridecadeoxynukleotid, verfahren zu seiner herstellung und verwendung"
US4464359A (en) * 1981-04-10 1984-08-07 Research Corporation (2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof
DE3280400D1 (de) * 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4393201A (en) * 1981-11-04 1983-07-12 The Wistar Institute DNA Which codes for glycoprotein of era-strain rabies virus

Also Published As

Publication number Publication date
IT8468021A0 (it) 1984-10-16
SE466482B (sv) 1992-02-24
CH667593A5 (de) 1988-10-31
DK493584D0 (da) 1984-10-16
GB2148302B (en) 1987-10-07
SG31088G (en) 1988-09-30
ATA329284A (de) 1990-07-15
DK168061B1 (da) 1994-01-31
IE57987B1 (en) 1993-06-02
SE8405133D0 (sv) 1984-10-15
GB2148302A (en) 1985-05-30
PH21629A (en) 1987-12-11
NL8403163A (nl) 1985-05-17
IT8468021A1 (it) 1986-04-16
IT1179144B (it) 1987-09-16
AU3423984A (en) 1985-04-26
MTP957B (en) 1985-05-27
AU578625B2 (en) 1988-11-03
LU85594A1 (de) 1985-04-02
FR2553420A1 (fr) 1985-04-19
FR2553420B1 (fr) 1988-04-01
AT392081B (de) 1991-01-25
GB8425799D0 (en) 1984-11-21
US4689320A (en) 1987-08-25
SE8405133L (sv) 1985-04-18
DE3437852A1 (de) 1985-05-23
BE900827A (fr) 1985-02-15
NZ209840A (en) 1988-11-29
IE842668L (en) 1985-04-17

Similar Documents

Publication Publication Date Title
DK493584D0 (da) Fremgangsmaade til inhibering af vaeskt af virus og anti-viralt middel
DK137382A (da) Elektrolyt og fremgangsmaade til elektroafsaetning af kobber
DK66884D0 (da) Fremgangsmade og indretning til flydende anlaeg af ark
DK532083D0 (da) Fremgangsmade og middel til forhindring af kedelstensaflejring fra vand
DK341183A (da) Fremgangsmaade til oxidation af alkoholer til aldehyder og/eller ketoner
DK80184A (da) Fremgangsmaade og kredsloeb til behandling af impulser
DK164508C (da) Fremgangsmaade til fremstilling af natriumcefuroxim
DK530684D0 (da) Fremgangsmaade og kredsloeb til korrektion af doedtidstab ved straalingshaendelser
DK160869C (da) Analogifremgangsmaade til fremstilling af substituerede urinstoffer og thiourinstoffer
DK474884A (da) Antiviralt middel og fremgangsmaade til administration af samme
DK112483A (da) Fremgangsmaade og middel til anbringelse af krympefolie paa palleterede godsstabler
DK205982A (da) Fremgangsmaade og middel til flegmatisering af hydroxy-benzotriazoler hydroxy-oxo-dihydro-benzotriaziner
DK217883D0 (da) Fremgangsmade til nukleofil substituering af uaktiverede aromatiske og heteroaromatiske substrater
DK31481A (da) Substituerede benzonitriler ogmfremgangsmaade og midler til haemning af virus
DK78784A (da) Fremgangsmaade til separering af oploesninger
DK524184A (da) System af laase og noegler
DK103084D0 (da) Middel til behandling af arteriosclerosis
DK430883A (da) Fungicidt middel og fremgangsmaade til bekaempelse af svampe
DK295184D0 (da) Fremstilling af monoalkylerede dihydroxybenzener og derved fremstillede hidtil ukendte forbindelser
DK302382A (da) Fremgangsmaade og middel til at foroege formeringen af pattedyrog fugle
DK626784D0 (da) Fremgangsmaade og rensning af alkylerede antraquinoner
DK153932C (da) Fremgangsmaade og anlaeg til enkeltvis emballering af fjerkrae i poser
DK159182C (da) Herbicidt middel og fremgangsmaade til bekaempelse af uoensket vegetation
DK84183A (da) Benzyletherderivater af pentiter og fremgangsmaade til fremstilling deraf
DK161245C (da) Haandteringsbeholder af en aluminiumlegering

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired